Status:
UNKNOWN
Monitoring the Changes of Tumor-related Biomarkers Before and After Pulmonary Nodule Biopsy.
Lead Sponsor:
China-Japan Friendship Hospital
Conditions:
Lung Cancer
Eligibility:
All Genders
18-80 years
Brief Summary
In the past few years, circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), microRNAs, autoantibodies, and T-cell receptor repertoire are new biomarkers of liquid biopsy in cancer, which has...
Eligibility Criteria
Inclusion
- Confirmed as suspected lung cancer patients with pulmonary nodules (single or multiple) by CT scans, and the maximum diameter of nodule is between 8mm and 3cm;
- Male or female, with age of 18\~80 years;
- Agree to take the pulmonary nodule biopsy, and sign the Informed Consent.
Exclusion
- With severe comorbidities and unable to participate in this study;
- Diagnosed with acute respiratory tract infection, for instance fungus, mycobacterium tuberculosis or other bacteria, virus, etc., one month prior to the study recruitment;
- Pregnant or maternal women;
- Diagnosed with other carcinoma, and the pulmonary nodules suspected of stemming from other sites;
- Unable for regular follow-ups according to the research protocol;
- Blood sample is not qualified for biomarker testing.
Key Trial Info
Start Date :
January 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT03397355
Start Date
January 1 2018
End Date
December 31 2022
Last Update
January 31 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China, 100029